Low-density lipoprotein cholesterol (LDL-C)–lowering therapies have yielded significant value to society through reduced costs for both fatal and nonfatal cardiovascular disease events. The vast majority of this value has accrued to patients.
Katie Everson, MS
Advertisement
Articles by Katie Everson, MS
Advertisement
Latest Updated Articles
- Two Steps Forward, One Step Back: 50 Years of Societal Value From LDL-C–Lowering Therapies
Published: April 13th 2021 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA to Restrict Ingredients Used in Mass-Marketed Compounded GLP-1s, Crack Down on Misleading Ads
2
Overcoming Mistrust in Clinical Trial Enrollment Through Community Resources: Susan Vadaparampil, PhD, MPH
3
New Legislation Aims to Address Transparency in PBMs as First Major Step in Reform
4
Medicare’s 3-Day Rule Reinstatement Lengthened Hospital Stays Without Cost, Outcome Benefits
5